Hospital Universitario Nuestra Seora de Candelaria

Unidad de Investigacin
Nefrobiologa y riesgo cardiovascular
Juan Francisco Navarro Gonzlez.
Jefe de Servicio de la Unidad de Investigacin.
Facultativo Especialista de Nefrologa del HUNSC.
Profesor colaborador docente
(Dpto.Medicina Interna) de la ULL.
Francisco Navarro

Inflammation is now considered a phenomenon of great relevance in many diseases. Our research examines the implications of the inflammatory phenomenon in the context of highly prevalent diseases in humans: atherosclerosis, hypertension, diabetes mellitus, etc. This approach is done from different perspectives. First, from a pathogenic point of view, through an integral strategy at different levels: experimental, clinical, molecular and genetic. Therefore, it would be possible to increase our knowledgment about the intimate mechanisms by which inflammatory pathways participate in the development and progression of these diseases and their complications. Secondly, with a therapeutic perspective, analyzing what mechanisms and pathways may provide new therapeutic targets for these diseases. And finally, with a translational research perspective, our group will develop and promote the clinical applicability of new potential treatment strategies, both through initial analysis in animal models and finally with the promotion of clinical trials to test the real applicability at the clinical setting.

Funded Projects

  • Spanish Ministry of Health and Social Policy  (2010-2012).
    “Effect of statin-aspirin vs statin-pentoxifylline combination on atherosclerotic lesion”.
    Juan Francisco Navarro González. Principal Researcher.
  • Spanish Society of Nephrology (2010-2011).
    “Drosophila melanogaster nephrocites as experimental model for diabetic nephropathy study” (Ref. SEN 846). Juan Francisco Navarro González. Associate Researcher.
  • Canary Research and Health Foundation (FUNCIS) (2009-2010).
    “Implications of linfotoxin-alfa/tumor necrosis factor-a on atherosclerotic lesion in patients with ischemic cardiopathy: biochemical, molecular and genetic approach”
    (Ref.: PI18/07). Juan Francisco Navarro González. Principal Researcher.
  • Ministry of Health. Carlos III Health Institute (2008-2010).
    “Sexual dimorphism of tumor necrosis factor-alfa system and atherosclerotic vascular lesion in coronary hearth disease. Biochemical, molecular and genetic approach” (Ref.: PI 070870). Juan Francisco Navarro González. Principal Researcher.
  • Ministry of Health. Carlos III Health Institute (2008-2010).
    “Evaluation of renoprotective effect of pentoxifyllline in patietns with chronic kidney disease secondary to diabetic nephropathy” (Ref.: EC 07/90021). Juan Francisco Navarro González. Principal Researcher.
  • Spanish Society of Nephrology (2007-2008).
    “Clinical and genetic characterization of inflammatory substrate in patients with diabetic nephropathy. Relationship with renal disease progression”. Juan Francisco Navarro González. Principal Researcher.
  • Canary Research and Health Foundation (FUNCIS) (2005-2006).
    “Inflammatory cytokine gene polymorphisms in patients with chronic kidney disease stage 5: relationship with cardiovascular risk factors and comorbidity”. Juan Francisco Navarro González. Principal Researcher.
  • Canary Research and Health Foundation ( (FUNCIS) (2002-2004).
    "Polymorphisms of inflammatory response genes in the genetic susceptibility to diabetic nephropathy” (Ref.: 45/02). Juan Francisco Navarro González. Principal Researcher.
  • Spanish Society of Nephrology (2002-2004).
    “Expression of inflammatory response genes in experimental diabetic nephropathy”. Juan Francisco Navarro González. Principal Researcher.
  • Instituto de Salud Carlos III - Fondo de Investigacin Sanitaria (2011-2013).
    "Enfermedad cardiovascular subclnica en descendientes de pacientes afectos de cardiopata coronaria. Caracterizacin y relacin fisiopatolgica con el sistema biolgico del factor de necrosis tumoral-alfa" (Ref. PI10/00576). Juan Francisco Navarro Gonzlez. Investigador principal.

Clinical Trials

  • Study of Heart And Renal Protection (SHARP): Investigation of the effects of lowering cholesterol in heart disease in patients with renal insufficiency. Final version July 14, 2003.
    Sponsor: University of Oxford
    Protocol Code: CTSUSHARP1 (SHARP) 2005
    Researcher: Juan Navarro González.
  • Phase III, open, multicenter clinical trial to assess the effect of the renin-angiotensin system with converting enzyme inhibitors (ACEI) (lisinopril), AT1 receptor blockers (ARA2) of angiotensin II (irbesartán), and their combination on the progression of chronic renal failure (CRF) in the nephropathy of type 2 diabetes mellitus".
    Promoter: Dr. José Luño Fernández. Hospital Gregorio Marañón, Madrid
    Protocol Code: PI031707 (PRONEDI). 2005
    Researcher: Juan Navarro González.
  • Open, randomized, controlled study to evaluate inflammatory properties of sevelamer (Renagel ®) in patients undergoing chronic hemodialysis.
    Promoter: Scientific Association for Kidney Research (ACINEF).
    Protocol Code: CAN-NEFRO-20058-01. 2005
    Principal Researcher: Juan Navarro González.
  • Randomized, double-blind, placebo-controlled and parallel groups study to evaluate the effect of Endothelin receptor Antagonist Avosentano to assess the time necessary to duplicate serum creatinine levels on end-stage renal disease, or death in patients with type 2 diabetes mellitus and diabetic nephropathy.
    Promoter: S.P.P.
    Protocol Code: Speedel Pharma Ltd. SPP301CRD15. 2006
    Researcher: Juan Navarro González.
  • "The Collaborative Study Group": The Effect of Sulodexida in overt type 2 diabetic nephropathy".
    Promoter: Keryx Biopharmaceutica.
    Protocol Code: KRX-101-401. 2007
    Researcher: Juan Navarro González.
  • Clinical noncomercial test: Evaluation of renoprotective effect of pentoxifyllline in patients with chronic kidney disease secondary to diabetic nephropathy (Ref.: EC 07/90021).
    Promoter: Juan Navarro González
    Funding Entity: FIS (Carlos III Health Institute).
    Principal Researcher: Juan Navarro González.